Key Takeaways
- • Bain Capital's Life Sciences team, led by partner Adam Koppel, is targeting scaled investments of $100 million or more in biopharma, underwriting value-creation events such as Phase II or Phase III clinical data readouts.
- • Private equity firms are increasingly comfortable entering biotech as growth equity investors due to sector maturation, rising capital requirements for late-stage trials, and PE firms' improved ability to conduct technical diligence on complex life sciences assets.
- • Koppel employs a tranched deal structure for large biotech investments to reduce investor risk while maintaining capital discipline, making these scaled investments sustainable despite binary clinical trial outcomes.
- • The Bain Capital Life Sciences team, which Koppel has led since rejoining in 2016, manages over $7 billion in assets under management focused on growth equity and public market investing across the biopharma sector.
Summary
Private equity's expanding presence in biopharma reflects the maturation of the life sciences sector and growing capital needs among biotech companies, according to Adam Koppel, partner at Bain Capital Life Sciences. Speaking to BioCentury, Koppel attributed PE firms' increasing comfort with biotech investments to the convergence of larger deal sizes with institutional investors' enhanced technical capabilities. "Now that the scale is matching the ability to do good diligence and make good investment decisions, you are seeing more comfort in entering the space," he stated.
Koppel outlined Bain's investment strategy for scaled transactions, typically $100 million or larger, which focus on identifying and underwriting major value-creation milestones in drug development—particularly Phase II and Phase III clinical data events. This approach requires substantial preparatory diligence to build conviction ahead of the binary outcomes inherent in clinical trials. Koppel emphasized that heavily tranching these deals addresses two critical concerns: reducing investor downside risk while simultaneously enforcing disciplined capital allocation across multiple funding rounds.
The sustainability of large-scale biotech investments, Koppel noted, is driven by both structural and market factors. On the structural side, tranched deal arrangements mitigate risk exposure. Simultaneously, the biopharma sector's growth has created persistent demand for large capital pools to finance late-stage development and commercial launches, ensuring continued opportunities for scaled PE investments. Koppel initially joined Bain in 2003 and led its public equity healthcare team for a decade before departing to serve as executive vice president of corporate development and strategy at Biogen. He returned to Bain in 2016 to build its life sciences platform, which now manages more than $7 billion in assets under management.
Koppel outlined Bain's investment strategy for scaled transactions, typically $100 million or larger, which focus on identifying and underwriting major value-creation milestones in drug development—particularly Phase II and Phase III clinical data events. This approach requires substantial preparatory diligence to build conviction ahead of the binary outcomes inherent in clinical trials. Koppel emphasized that heavily tranching these deals addresses two critical concerns: reducing investor downside risk while simultaneously enforcing disciplined capital allocation across multiple funding rounds.
The sustainability of large-scale biotech investments, Koppel noted, is driven by both structural and market factors. On the structural side, tranched deal arrangements mitigate risk exposure. Simultaneously, the biopharma sector's growth has created persistent demand for large capital pools to finance late-stage development and commercial launches, ensuring continued opportunities for scaled PE investments. Koppel initially joined Bain in 2003 and led its public equity healthcare team for a decade before departing to serve as executive vice president of corporate development and strategy at Biogen. He returned to Bain in 2016 to build its life sciences platform, which now manages more than $7 billion in assets under management.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.